Cannabis and Digestive Health: Clinical Risks

 At the 2026 Journées francophones d'hépato‑gastroentérologie et d'oncologie digestive (JFHOD), the French‑language conference on hepatology, gastroenterology, and digestive oncology, gastroenterologist Fabien Wuestenberghs, from France's Greater Paris University Hospitals, addressed the question, "Is cannabis dangerous for the digestive tract?" At the start of his talk, Wuestenberghs reminded listeners that "cannabis encompasses all derivatives of the Cannabis sativa plant, mainly consumed as dried flowers, but also as gummies (edibles) or resins. The active substances are the phytocannabinoids, notably tetrahydrocannabinol, which is responsible for the psychoactive effects."

Non-Digestive Effects

Before discussing cannabis' harms to the digestive tract, Wuestenberghs reviewed the substance's non‑digestive effects: "Major side effects include addiction; psychiatric disorders, notably the risk of psychosis; cognitive deficits in attention and memory; respiratory problems related to inhalation; cardiovascular effects such as tachycardia; and accidents due to reduced alertness. Vulnerable populations, such as pregnant women and adolescents with developing brains, are particularly at risk."

Inhibitory Effect on the Digestive System

On the digestive side, cannabis has an overall inhibitory effect, Wuestenberghs said: "At the level of the esophagus, it has been shown to reduce the tone of the lower sphincter and decrease transient sphincter relaxations after meals. In addition, it slows gastric emptying."

Nausea

Regarding nausea, cannabis can have beneficial effects in some cases: Low doses can improve this symptom, as observed in certain studies of diabetic gastroparesis and chemotherapy‑induced nausea and vomiting. However, prolonged use can cause nausea and vomiting.

Small Intestine

At the level of the small intestine, data from animal models suggest improved barrier function, reduced inflammation, and inhibition of colonic motility, which can sometimes lessen certain functional pains, Wuestenberghs continued.

Cannabinoid Hyperemesis Syndrome

The main adverse effect is cannabinoid hyperemesis syndrome, characterized by recurrent episodes of nausea and vomiting and abdominal pain, similar to cyclic vomiting syndrome. "This syndrome occurs exclusively in heavy, regular cannabis users; its diagnosis is based on symptom resolution after complete cessation of use, although the process can be delayed because cannabis accumulates in adipose tissue. A distinctive sign reported by patients is symptom relief from hot baths or showers," Wuestenberghs said. The underlying pathophysiology is not yet fully elucidated, but it may be related to peripheral desensitization of CB1 receptors in the enteric nervous system, changes in gastric motility, psychological and genetic factors, and overexpression of the TRPV1 receptor, he said. There are experimental topical treatments aimed at targeting these mechanisms.

Cannabidiol (CBD)

"The cannabidiol (CBD) has shown symptomatic benefit in some cases of idiopathic or diabetic gastroparesis, despite worsening gastric emptying," Wuestenberghs said. Its therapeutic use remains controversial.

Diagnosis and Management

"It's important not to attribute digestive symptoms too quickly to cannabis without ruling out other diagnoses. The timing between consumption and symptoms is essential to assess. A trial of stopping cannabis for at least one month is recommended to confirm a causal link," Wuestenberghs recommended. He also said clinicians should consider the frequent possibility of co‑use of other substances — for example, cocaine or opioids — that can influence digestive symptoms. The therapeutic approach favors cessation of use and referral to addiction specialists when necessary. "Disorders related to use are common; it is essential to check patients' substance‑use histories. The principal effects are inhibitory on the digestive tract, with cannabinoid hyperemesis syndrome as a notable condition," he concluded.

https://www.medscape.com/viewarticle/cannabis-and-digestive-health-clinical-risks-2026a1000b1g

Urologists Reckon With Ketamine’s Toll on the Bladder

 Heavy use of ketamine can damage the urinary tract, sometimes irreversibly.

Pharmaceutical and surgical treatments can help, but the most important step is to stop taking the drug, according to physicians who treat patients with ketamine cystitis or uropathy.

Quitting the anesthetic is not easy, partly because the drug creates a vicious cycle.

“Ketamine cystitis is painful, and ketamine is a very powerful painkiller,” Laetitia M.O. de Kort, MD, PhD, with University Medical Center Utrecht in Utrecht, Netherlands, said in a presentation at the European Association of Urology (EAU) 2026 Annual Meeting.

de Kort and her team run a ketamine cystitis clinic where an addiction specialist works with patients to stop use of the drug while clinicians may also prescribe medications for pain and symptoms of overactive bladder.

Shiv Sarna, MBBS, a surgical trainee at Norfolk and Norwich University Hospital, Norwich, England, treats patients at his hospital’s ketamine bladder clinic, which opened in 2021.

At the EAU meeting, he also emphasized the importance of ketamine cessation.

“The best treatment isn’t a scalpel; it’s abstinence. Once we treat the addiction, the bladder usually follows,” Sarna said.

Pathophysiology

Ketamine and its metabolites appear in high concentrations in urine. They can irritate the bladder wall and lead to ulcers, de Kort explained. Patients with ketamine cystitis typically have severe urgency, frequency, pain, and gross hematuria.

When the condition is still reversible, histologic changes in the bladder include inflammation, urothelial erosion, microvascular injury, and apoptosis. At a later, irreversible state, fibrosis of the bladder wall occurs.

Medically, ketamine is used in anesthesiology and more recently for severe depression with a therapeutic dose of up to 200 mg a week, de Kort said. But the drug is also popular among recreational users, who snort or smoke it for its sedating, dissociative, and hallucinogenic effects. People who use ketamine recreationally might take 150 mg/d, and those with addiction might use several grams per week, she said.

Research has shown a quarter of people who regularly use ketamine recreationally may have urinary symptoms and using 1 g/d or more heightens the risk.

‘New Pandemic’

In a session at the EAU meeting, Benoit Peyronnet, MD, PhD, with University of Rennes in Rennes, France, called ketamine cystitis “the new pandemic” in urology in Europe. 

Ketamine cystitis was a focus at a urology conference in France, and experts there have published guidelines on the management of the condition.

The International Consultation on Incontinence Research Society has outlined treatment strategies, proposing initial treatment with oral medications. After quitting ketamine, patients may receive intravesical therapy for initial bladder fibrosis. For irreversible damage, patients may undergo reconstructive surgery.

At an addiction treatment center in England, adults with ketamine addiction have been fitted with urine bags, the BBC reported in March.

One surgeon there told the news agency he has seen an uptick in patients with ketamine-induced bladder problems.

In the US, the potential complication was raised when The New York Times reported last May that Elon Musk had told people he had experienced bladder issues from taking ketamine. Musk responded on social media by denying taking drugs. (“I tried *prescription* ketamine a few years ago and said so on X, so this not even news,” he wrote. “It helps for getting out of dark mental holes, but haven’t taken it since then.”)

Patient Outcomes

de Kort presented data from a cohort of nearly 180 patients at the Dutch ketamine cystitis clinic. Patients typically were male, in their late 20s, and taking an average ketamine dose of 22 g/wk. Patients generally had severe daytime and nighttime urinary frequency, hematuria, and high pain scores.

The team found patients who stopped ketamine improved more with oral medications than those who continued using the drug.

Second-line treatment may consist of therapies used in other chronic bladder pain syndromes, such as instillations, hydrodistension, botulinum toxin injections, or laser coagulation.

Most of the 54 patients who received laser coagulation improved or were symptom-free and were satisfied after treatment, according to de Kort.

In refractory cases, major surgery is the next step.

“Of course, we want to avoid this in this very young patient group,” she said. Earlier treatment with intravesical therapy may be warranted to try to avoid major surgery, de Kort added.

In 18% of the cohort, the condition also involved the upper urinary tract, which may be caused by vesicoureteral reflux.

In addition to the bladder problems, sexual function may be impaired. Erectile dysfunction is common in men with ketamine cystitis, and research shows sexual dysfunction may be common in women with the condition as well.

A Multidisciplinary Approach

At Sarna’s ketamine bladder clinic, urology, substance misuse specialists, pain specialists, and community addiction services are part of the treatment approach.

Of 229 patients managed in the clinic, 112 remained in active treatment, 110 were discharged, and seven died from renal or hepatic failure or overdose. Of those discharged, about 42% had stopped using ketamine and experienced improvements in their lower urinary tract symptoms. About a quarter of the current patients were discharged previously but were re-referred to the clinic.

Approximately 56% were male, and the mean age was 28 years, with a range of 16-59 years. Patients were exposed to ketamine for almost a decade on average and reported taking an average dose of 8.4 g/d.

“The resulting damage is severe,” Sarna said. “Our patients had a mean bladder capacity of only 179 mL. But this goes far beyond just the bladder: 13% of our cohort had hydronephrosis on referral; 26% had cholangitis.”

Still, patients can improve, Sarna said. “For those who engage and achieve abstinence, the results are clear: Over half of our cohort have reported a significant symptomatic improvement.” 

Peyronnet disclosed having ties to AbbVie, Intuitive, Medtronic, Boston Scientific, Contura, Pierre Fabre, Ipsen, IBSA, Lilial, and Schwa Medico. de Kort and Sarna had no disclosures.

https://www.medscape.com/viewarticle/urologists-reckon-ketamines-toll-bladder-2026a1000blo

Cosmetic Eyelash Extensions Independently Associated With Dry Eye in Observational Study

 Cosmetic procedures to lift or extend eyelashes are linked to dry eye, new research shows.

Nearly 90% of patients in the observational study reported experiencing symptoms of dry eye and other ocular conditions after receiving the cosmetic procedures, researchers reported at the American Society of Cataract and Refractive Surgery (ASCRS) 2026 Annual Meeting.

“Although these procedures are generally perceived as safe and are associated with high user satisfaction, case reports and small observational studies have described a range of potential ocular surface effects,” such as allergic blepharoconjunctivitis, keratitis and epithelial defects, and dry eye symptoms, said Pamela Capellan, MD, MBA, an ophthalmology resident physician at Baylor College of Medicine in Houston, who helped conduct the research.

Lash procedures are becoming increasingly popular, said Masako Chen, MD, an ophthalmologist at New York Eye and Ear Infirmary of Mount Sinai in New York City, who was not involved in the study.

“It’s a huge trend right now,” said Chen, who suggested clinicians should start asking about lash procedures when patients come in with dry eye or irritation. “We think about eye makeup use, but other procedures may not be totally obvious,” she told Medscape Medical News.

However, both she and the researchers stopped short of recommending people steer clear of lash procedures based on the risk. “It’s a personal choice,” Chen said. “But I think with patients with dry eye, I would say use your caution.”

“I think as someone myself who also gets some of these lash modifications and have friends who do, it is very difficult to tell patients not to do something,” Capellan said. “If they are having symptoms or becoming symptomatic, then how can we help them with aggressive lubrication and treatments and looking at the frequency or even the location and the kind of chemicals that they’re using as well?”

Among 49 women surveyed, 24 had recently undergone lash extensions or lifts. That group had an average score of 29.9 on the 100-point Symptom Assessment in Dry Eye scale compared with 4.4 among women who had never or not recently undergone the procedures (P = .0003). The association retained statistical significance after controlling for age, race, ethnicity, and use of contact lenses, Capellan and her colleagues reported (P = .0010).

The same pattern was seen in the 22-point Dry Eye Questionnaire-5, with averages of 7.1 among recent users vs 3.4 among the control individuals (P = .0023; P = .0497 after adjustment for age, race, ethnicity, and use of contact lenses).

Notably, 88.5% of lash extension users reported at least one ocular symptom, and 37% reported prior complications from the cosmetic procedure, Capellan’s group reported.

The most common ocular symptoms were itching and tearing (50% of participants each), followed by redness, dryness, and burning (38.5% each). None of the women in the study reported blurred or disturbed vision.

Despite the prevalence of eye adverse effects, all the women who had used lash services said they were satisfied with the procedures and intended to repeat them. About 58% said they would tolerate ongoing eye symptoms rather than stop getting lash extensions. Indeed, 63% said they got them monthly.

Notably, none reported being advised by an eye care professional to stop doing so.

“The disconnect between symptom burden and care-seeking behavior underscores a substantial gap in patient education and proactive clinical counseling regarding ocular surface health risks associated with cosmetic lash procedures,” the researchers concluded.

The single-center study included 24 recent users of lash procedure (in the prior 1-2 months), five nonrecent users (over 3 years since the last procedure), and 20 age-matched women who never used the products, recruited from specialty clinics including ophthalmology and dermatology. Telephone-based questionnaires captured demographics, lash practices, and ocular symptoms.

Never users tended to be older (mean age, 49.2 years) than nonrecent or recent users (34.8 and 41 years, respectively). A history of ocular comorbidity was uncommon across the groups.

The mean duration of use was about 41 months, with about 45 lifetime lash procedures on average. All the women who used lash procedures received extensions, and 27.6% also reported receiving lifts.

More frequent, longer duration, and higher cumulative use of lash procedures was not significantly associated with eye symptoms.

“Symptom severity appears related to recent exposure rather than cumulative duration or frequency of use, suggesting an acute rather than chronic dose-dependent mechanism,” Capellan and her colleagues reported.

The retrospective study leaves open questions of whether certain approaches to lash lifts or extensions are riskier than others and what might be their long-term impacts, such as repeated chemical conjunctivitis altering homeostasis of the tear film or worsening meibomian gland dysfunction, Chen said.

“It’s definitely helpful from my standpoint to have a study to go to when I counsel patients about this,” Chen said, but “long-term studies would be helpful so that we can properly counsel our patients.”

The researchers and Chen disclosed having no relevant financial conflicts of interest. 

https://www.medscape.com/viewarticle/cosmetic-eyelash-extensions-independently-associated-dry-eye-2026a1000bku

Outsized Ambitions at Brookfield Asset Management as it Doubles Down on Private Credit

 

In the asset management sector, the two most meteoric entrepreneurial success stories of recent decades have undoubtedly been BlackRock and Brookfield-the former with its ETFs, the latter with its alternative management solutions.

The Brookfield empire is based on several pillars: real estate, particularly office space with trophy properties in New York and London; renewable energy; infrastructure; insurance; private equity; and, for the past few years, the now highly controversial private credit segment.

The group's highly complex structure was partially clarified in December 2022 through the partial spin-off of Brookfield Asset Management, its asset management franchise, which is listed independently of the holding company Brookfield Corporation, although the latter retains three-quarters of the capital.

The rationale behind this operation was that the asset management platform's capital-light, highly profitable, and high-visibility model deserved a valuation premium over the holding company—a premium that remained elusive as long as the former was obscured within the latter's Byzantine structure.

Brookfield Asset Management has experienced extraordinary growth in its fee-bearing assets under management (AUM) since 2020, rising from $277bn at the end of 2020 to $563bn by the end of 2025, 90% of which is described by management as "permanent" capital. In this respect, its management fees have doubled from $1.3bn to $2.7bn over the period.

Over the last five years, Brookfield has deployed an impressive capital-raising machine, with five times more additional capital raised in 2025 than in 2020. This was driven notably by a breakthrough among pension funds—which previously favored liquid market strategies over alternative solutions—and, of course, by the private credit segment, which alone accounts for nearly half of the additional fundraising.

Most striking is that Brookfield continues to display outsized ambitions, promising to double its fee-bearing AUM once again to reach $1.2 trillion by 2030. This expansion is expected to stem primarily from its breakthrough in asset management for insurers, which has so far faced no regulatory opposition.

In terms of deployment, the infrastructure, energy, and private equity segments are all expected to double. However, it is particularly in its private credit strategies that Brookfield intends to accelerate at full throttle, notwithstanding the current sulfurous headlines.

Should this plan materialize, distributable earnings to shareholders are expected to double from $1.6bn in 2025 to $3.6bn in 2030. Since Brookfield Asset Management distributes nearly all of this amount in dividends, this would translate into a doubling of the payout within a four-year horizon.

The current yield on Brookfield Asset Management shares exceeds 4%, marking an all-time high, while the operating profit multiple is at an all-time low, even though it still reflects positive growth projections. Notably, Brookfield Asset Management is now valued at the "fair value" assigned to it by management during the late 2022 spin-off.

Proponents of the stock might see this as an opportune entry point. Others, more cautious, will point out that the Brookfield empire has long been criticized for its opaque structure and occasionally creative accounting, blurred notably by inter-subsidiary transactions and other complexities, leading them to remain on the sidelines of both the holding company and the asset management platform.

https://www.marketscreener.com/news/outsized-ambitions-at-brookfield-asset-management-as-it-doubles-down-on-private-credit-ce7e50dfd98bf22c

US destroyer interdicts two oil tankers attempting to leave Iran, official says

 

 A U.S. destroyer interdicted two oil tankers attempting to leave Iran on Tuesday, a day after U.S. President Donald Trump's blockade went into effect, and instructed them to turn around, a U.S. official said, speaking on condition of anonymity.

The ships had left Chabahar port on the Gulf of Oman and were contacted by the warship via radio communication, the official said. It was unclear whether any further warnings were given.

The disclosure adds further detail to the start of Trump's blockade, which aims to pressure Iran to end its effective closure of the Strait of Hormuz, a choke point for about 20% of the world's oil. 

Trump is hoping the blockade will force Iran to accept America's terms for ending a war launched by the U.S. and Israel on February 28, including opening up the Strait of Hormuz. Trump says that was also a condition of a week-old ceasefire with Iran due to expire next week.

Experts are cautious. Noam Raydan at The Washington Institute for Near East Policy said tracking data did show one tanker making a U-turn after the start of the blockade but cautioned that a lot of ships working with Iranian oil go dark.

"We just don't know yet how effective it is. We are still in day two," Raydan said.

The U.S. official said the two tankers were among the six merchant vessels the U.S. Central Command said in a statement earlier on Tuesday had followed orders to "turn around to re-enter an Iranian port on the Gulf of Oman."

Central Command said no ships have made it past the blockade since it went into effect on Monday at 10 a.m. in Washington (1400 GMT).

MORE THAN 10,000 TROOPS

The blockade is a massive undertaking involving more than 10,000 U.S. forces, over a dozen warships and dozens of aircraft, the U.S. military says.

The U.S. military says it will support freedom of navigation for vessels transiting the Strait of Hormuz, as long as they are not going to or from Iran.

Trump announced the blockade following the breakdown of weekend talks to end the war. Oil prices jumped back above $100 a barrel before easing on Tuesday on hopes of further talks.

If Trump's strategy succeeds, he would eliminate Iran's greatest point of leverage in negotiations with the U.S. and clear the strait again for global trade. But a blockade, experts say, is an act of war that requires an open-ended commitment of a significant number of warships.

It could also trigger fresh retaliation from Tehran and put tremendous strain on an already fragile ceasefire.

Iran's threats to shipping have caused global oil prices to skyrocket about 50%. Roughly 5,000 people have died in the hostilities. 

Thousands of U.S. military strikes have severely weakened Iran's military. But analysts say Tehran has emerged from the conflict as a vexing problem for Washington, with a more hard-line leadership and a buried stockpile of highly enriched uranium.

Raydan said to expect likely Iranian retaliation if the blockade succeeds and lasts for an extended period, noting Iranian threats to strike Gulf states that host U.S. forces and Iran's past attacks on ships.

"We're in the testing period," Raydan said. 

https://www.marketscreener.com/news/us-destroyer-interdicts-two-oil-tankers-attempting-to-leave-iran-official-says-ce7e50dfd08bfe27

Mossad Chief Declares Mission In Iran Not Over Until Regime Falls

 A two-week Iran-US-Israel ceasefire is still in effect despite the collapse of last weekend's Islamabad talks, where the big hang up was fierce disagreement over Iran's nuclear development. The clock is ticking amid efforts to hold more direct talks by the end of this week.

What's unlikely to help things move along is a fresh statement from Mossad Director David Barnea. While speaking at a Holocaust Remembrance Day ceremony in Jerusalem on Tuesday, he boasted that Mossad assets have been operating from the heart of Tehran and that the fight is not over until there's regime collapse or overthrow.

He said of Israel's premier intelligence agency that it operated "in the heart of Tehran" during the recent US-Israeli campaign against Iran, and further that "We brought precise intelligence to the Air Force, and we hit missiles that threatened Israel."

Israeli Prime Minister's office

"But our mission has yet to be completed," the spy chief added. "We didn’t think that this mission would be completed immediately with the end of the battles. But we planned intensively for our campaign to continue and achieve results even in the period after the strikes in Tehran."

Mossad's involvement in counter-Iran action, he continued, will end "only when this radical regime is replaced."

Barnea made clear that regime change in Iran "is our mission. We will not stand by, watching, in the face of another existential threat."

Ironically, Israeli media is still trying to pour cold water on persistent reporting of an Israeli role in convincing the White House to unleash the massive bombing campaign on Iran:

Accordingly, the Mossad has rejected allegations that it has failed or that it tried to "sucker" the US into believing in delusions of regime change.

Barnea's public statement was the latest indication that he still believes regime change is possible, but that the war only helped set initial, more favorable conditions for such a change, and that significant additional work will be needed going forward.

Trump himself has at times suggested the aim is regime change, and at others has stated the opposite. But it does seem he actually believed Iranian state institutions would be quickly overthrown in some kind of brief Venezuela-style operation.

Prior reports out of Israel have painted a more realistic picture, however, stating that regime change in Iran - a country of over 90 million people and long-standing institutions - would be extremely difficult if not nearly impossible. And this is especially without ground forces, given air power is limited and does not work for this.

US wars spanning from Vietnam to Afghanistan have long demonstrated that aerial bombardment, even if massive, only goes so far. And even when there are 'boots on the ground' and nation-building, US efforts can be quickly unraveled, as the Taliban's reascendancy in Kabul in 2021 demonstrates.

https://www.zerohedge.com/geopolitical/mossad-chief-declares-mission-iran-not-over-until-regime-falls

Vindictive, Trump-hating Boasberg gets judicial beatdown he needed

by Monica Showalter

It's always good to see out-of-control judicial activists get smacked down, especially by their own peers.

Which brings us to Judge James Boasberg, who's done more than any of them to try to shut down President Trump's legitimate power to govern.

He's in the donkey seat now, berated by a higher court for his 'abuse of power,' as they put it.

According to the Washington Times:

A federal appeals court delivered an embarrassing spanking to U.S. District Judge James Boasberg on Tuesday, ordering him to shut down his “intrusive” criminal contempt of court investigation against the Trump administration.

The circuit court of appeals said not only is Judge Boasberg’s continued investigation “improper,” but his reasoning for why Trump officials could be prosecuted for contempt of court is a “dead end” because the judge is misreading his own orders.

Circuit Judge Neomi Rao said Judge Boasberg has crossed too many lines, risking damage to the separation of powers between the president and the courts.

Boasberg, recall, is the judge who told us what he was about when he gave former FBI attorney probation for literally altering a CIA email in order to obtain a FISA warrant to spy on a Trump campaign operative, claiming that Clinesmith "likely believed" the information was true (true because he made it so?) and simply took 'an inappropriate shortcut.' What kind of ace judicial reasoning is that, in what all the other FBI and federal employees understood very well was a jailtime offense? Anybody believe a request for an FBI FISA warrant is what it says it is after that one?

By 2025, Boasberg was well on his way to other abuses of power, ordering the Trump administration to halt the deportation of Venezuelan illegal aliens accused of being gang members to El Salvador, which was well within the Department of Homeland Security's powers to do, as the government of Venezuela refused to take them back and the written law says that when that is the case, the illegals can be repatriated to another country. Being gang members, the only good place for them was El Salvador's famous prison for them.

His ego wounded, he ordered the plane to be turned around mid-flight, as if that were practical and doable, something that might be reasonablee if these were defectors from North Korea facing death if they didn't. But under Boasberg, criminals were just as precious and important, and when the flight didn't come back, he launched his contempt of court case against the Trump administration, really really wanting those thugs to be brought back to America just because the Trump administration didn't.

According to CNN:

The decision comes nearly a year after Boasberg, the chief judge of the federal trial-level court in Washington, DC, said in a blockbuster ruling that “probable cause exists to find the government in criminal contempt” for defying his orders to temporarily halt the deportation of migrants under a powerful wartime authority invoked by President Donald Trump.

That's what's brought the current ruling, and the upper court didn't have nice things to say about this.

Boasberg wanted internal White House documents probed, when the law said that DHS had the authority to execute the repatriation flight, so Boasberg was appointing himself an overseer of the White House internal communications as a piddly district judge, in what was a fishing expedition for himself and his deep state pals, and national security, let alone respecting the presidency. suddenly wasn't important anymore.

CNN continued, citing the angry judges:

“The district court proposes to probe high-level Executive Branch deliberations about matters of national security and diplomacy. These proceedings are a clear abuse of discretion,” Judges Neomi Rao and Justin Walker said in the unsigned opinion.

“The district court has launched an intrusive criminal contempt investigation into whether the government acted willfully when it transferred suspected Tren de Aragua members to Salvadoran custody. But the end of this investigation is a legal dead end,” the court said.

Which is pretty humiliating, probably not to the average joe on the street, but among Boasberg's peers -- getting smacked down like that by a higher court over not following or understanding the basic rules of the game is the kind of thing incompetent miscreants get. Now he has to follow the law same as everyone else, thanks to some better class judges above him who know how to sort out his petty little egotistic games and great desire for power. Good move.

https://www.americanthinker.com/blog/2026/04/vindictive_trump_hating_judge_boasberg_gets_the_judicial_beatdown_he_needed.html